In the fall of 2023, very promising data from the ongoing phase 1b/2a study with Medivir's spearhead project fostrox in combination with Lenvima ® were presented. The combination has shown continued improved clinical benefit in patients with advanced primary liver cancer (HCC) and at ASCO-GI in
The clear clinical benefit and great medical need present an opportunity to accelerate the clinical development of fostrox with the ambition of becoming the first approved pharmaceutical therapy for the second-line treatment of HCC, a market worth
This and much more can be found in Medivir's Annual Report 2023, published today at the website;
https://www.medivir.com/investors/reports#FinancialReports2023
For additional information, please contact
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medivir/r/medivir-2023-annual-report-published,c3956627
The following files are available for download:
https://mb.cision.com/Main/652/3956627/2712076.pdf | Annual Report 2023 (PDF) |
https://mb.cision.com/Public/652/3956627/94d90d6aaa5efda3.pdf | Press release (PDF) |